Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases

Basit Öğe Kaydı
dc.authorid0000-0002-1530-0159en_US
dc.authorid0000-0001-5207-6240en_US
dc.authorid0000-0001-6762-1977en_US
dc.authorid0000-0001-7535-1735
dc.authorid0000-0002-1256-7325
dc.authorid0000-0001-9167-7815
dc.contributor.authorAkay, Aynur Pekcanlar
dc.contributor.authorKaya, Gamze Çapa
dc.contributor.authorBaykara, Burak
dc.contributor.authorDemir, Yusuf
dc.contributor.authorÖzek, Handan
dc.contributor.authorÖztürk, Yeşim
dc.contributor.authorTufan, Evren
dc.date.accessioned2021-06-23T19:42:28Z
dc.date.available2021-06-23T19:42:28Z
dc.date.issued2015
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractAttention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement.en_US
dc.identifier.doi10.2147/NDT.S87359
dc.identifier.endpage2911en_US
dc.identifier.issn1178-2021
dc.identifier.pmid26640376en_US
dc.identifier.scopus2-s2.0-84947787204en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2909en_US
dc.identifier.urihttps://doi.org/10.2147/NDT.S87359
dc.identifier.urihttps://hdl.handle.net/20.500.12491/8500
dc.identifier.volume11en_US
dc.identifier.wosWOS:000365302400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÖztürk, Yeşim
dc.institutionauthorTufan, Evren
dc.language.isoenen_US
dc.publisherDove Medical Press Ltden_US
dc.relation.ispartofNeuropsychiatric Disease And Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNeuroimagingen_US
dc.subjectDopamineen_US
dc.subjectNoradrenalineen_US
dc.subjectSLC6A3 Proteinen_US
dc.subjectHumanen_US
dc.subjectPragmatic Clinical Trialen_US
dc.subjectPilot Studyen_US
dc.titleAtomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three casesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
aynur-pekcanlar-akay.pdf
Boyut:
685.59 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu